logo
S. Korea develops world's 1st recombinant anthrax vaccine

S. Korea develops world's 1st recombinant anthrax vaccine

Korea Herald07-07-2025
South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency that could also open export markets for the new vaccine with fewer side effects, the government said.
The Korea Disease Control and Prevention Agency partnered with private firm GC Biopharma Corp. to develop the vaccine that, unlike conventional versions, eliminates the risk of exposure to toxins produced by Bacillus anthracis, a high-risk pathogen considered a potential bioterrorism agent.
The new vaccine, Barythrax inj., received regulatory approval from the Ministry of Food and Drug Safety in April. The approval allows South Korea to produce its own supply for the first time, ending its reliance on imports, the KDCA said at a press conference held last week.
"As demonstrated during the COVID-19 pandemic, infectious diseases can spread rapidly and cause massive damage in a short period of time. This underscores the importance of securing proactive response capabilities at the national level," said Kim Gab-jung, director general of the KDCA's department of disease diagnosis and analysis.
Kim said the achievement would help reduce vaccine import costs and enable faster, more stable responses in the event of national emergencies such as bioterrorism.
"Beyond infectious disease preparedness, the vaccine's development represents a major contribution to strengthening the country's overall public health security," the official said.
When asked whether tensions with North Korea factored into the vaccine's development, she said it was not specifically aimed at a potential attack from the North, but rather designed for national public health crisis preparedness.
"But one thing is clear: more thorough preparedness is required, as South Korea faces a different geopolitical situation compared to many other countries," she said.
Until now, South Korea had relied on imports of Biothrax, the US-made anthrax vaccine produced by Emergent BioSolutions Inc.
Regarding future stockpiles, the official said, "All newly secured doses will come from domestic vaccines, although specific plans cannot be disclosed at this stage."
On top of domestic stockpiling, the KDCA and GC Biopharma expect some overseas demand for Barythrax from countries without the capability to produce their own anthrax vaccines. Demand is expected to rise globally, as anthrax remains a public health concern -- particularly in regions experiencing recent outbreaks.
In 2023, Zambia reported more than 600 cases, while Uganda confirmed 251 in 2024. Laos, Thailand and the Democratic Republic of the Congo have also reported fatalities in recent years.
"To replace existing anthrax vaccine products on the market, we will focus on further improving product competitiveness and strengthening marketing activities to export Barythrax," said Lee Jae-woo, chief development officer at GC Biopharma's Development Division.
He added that the anthrax vaccine is part of GC Biopharma's social contribution efforts, noting that the company has earned significant profits from its varicella and influenza vaccines, its major revenue drivers.
The KDCA began basic research on anthrax vaccines in 1997, and GC Biopharma, formerly Green Cross, joined the development effort in 2002. Together, they invested a combined 30 billion won ($22 million) in the project.
Unlike traditional anthrax vaccines, Barythrax uses a non-toxin-producing strain of Bacillus brevis to produce only the protective antigen, the key to immunity. This method significantly reduces exposure to toxins and side effects, making the vaccine safer and more cost-effective than existing options.
No anthrax cases have been reported in South Korea since it was designated a notifiable disease in 2000.
GC Biopharma primarily exports varicella and influenza vaccines, as well as specialty drugs, such as Aliglo for treating immunodeficiency and Hunterase for treating hemophilia.
The company's sales rose 3.3 percent on-year to 1.68 trillion won last year, with exports accounting for 380 billion won, or 23 percent of the annual revenue. (Yonhap)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

No purchase needed: Businesses offer heat relief to the public
No purchase needed: Businesses offer heat relief to the public

Korea Herald

time11 hours ago

  • Korea Herald

No purchase needed: Businesses offer heat relief to the public

Amid the sweltering summer heat, commercial spaces such as convenience stores and banks in South Korea are opening their doors as cooling stations for the public. BGF Retail, the operator of CU convenience stores, said Thursday that its more than 18,000 branches nationwide will welcome all passersby, especially children, the elderly and pregnant women, to cool off without requiring a purchase. CU stores across the country began putting up signs about the policy on the same day. The latest campaign comes as the number of people suffering from heat-related illnesses continues to climb during the heat wave. On Tuesday alone, 136 people across the country were admitted to emergency rooms due to heat-related illnesses, nearly double the number on the previous day. So far, 1,860 people have fallen ill from the heat and nine have died, according to the Korea Disease Control and Prevention Agency. 'With the country's largest network of convenience stores, we aim to serve as a safety net for the public,' a CU official said. Local banks, which have long served as de facto heat shelters thanks to their strong air conditioning and cold water dispensers, also welcome people seeking relief from the summer heat, with some even setting up a designated space for them. Based on a 2018 agreement with the Financial Services Commission, banks, mutual finance institutions and savings banks have provided cooling spaces at 5,054 locations nationwide. In response to the record-breaking heat, they recently expanded the number to over 14,000 locations. These shelters will operate from 9 a.m. to 4 p.m. daily until Sept. 30, the end of the government-designated heat response period. However, despite the good intentions behind businesses' efforts to respond to the heat wave, some have voiced concerns about potential downsides to opening up private commercial spaces to the public. 'What if there's no seat left when I want to eat alone at a convenience store? I might not get a spot even if I pay,' one user wrote on X. Another commented, 'Banks are already packed with people cooling off. This will just make it more chaotic.' Intense heat is expected to continue into the weekend, with Seoul forecast to reach a high of 38 degrees Celsius on Saturday. Nighttime temperatures are also expected to remain high, nearing 30 degrees, a level considered a "super tropical night," according to the Korea Meteorological Administration.

SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

Korea Herald

time17-07-2025

  • Korea Herald

SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

SEONGNAM, South Korea, July 17, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. The candidate incorporates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu' to enhance protective efficacy. SK bioscience previously utilized adjuvants in its COVID-19 vaccine, 'SKYCovione', and now seeks to expand this technology to influenza vaccines as part of its broader platform strategy. NBP607B contains an adjuvant developed by the Vaccine Formulation Institute (VFI), a Swiss-based non-profit vaccine research organization. Comprising multiple immune-boosting components, the adjuvant is expected to induce strong immune responses and antibody production in elderly individuals. SK bioscience has proactively conducted non-clinical studies since 2023 and reported promising results. The Phase 1/2 clinical trial is scheduled to begin during the upcoming Northern Hemisphere flu season, enrolling approximately 320 older adults in Korea and abroad. The study will evaluate the vaccine's immunogenicity and safety compared to an approved high-immunogenicity flu vaccine, with interim results expected by 2027. This marks the first attempt by a Korean company to submit an IND to develop a high-immunogenicity influenza vaccine using an adjuvant. If successful, the company plans to leverage the platform for other vaccines and establish a competitive edge in the global high-value vaccine market. The development aligns with global health authorities' increasing recommendations for enhanced flu vaccines in high-risk groups. The U.S. Centers for Disease Control and Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) recommends high-dose or adjuvanted influenza vaccines for adults aged 65 and older. The World Health Organization (WHO) also supports the use of adjuvanted vaccines for vulnerable populations. In Korea, the Korea Disease Control and Prevention Agency (KDCA) has indicated that domestically developed high-immunogenicity vaccines may be considered for inclusion in the National Immunization Program (NIP) if they meet appropriate criteria. According to market research firm Mordor Intelligence, the global vaccine market is projected to grow from USD 83.9 billion in 2025 to USD 114.8 billion in 2030, with an average annual growth rate of 6.5%. Demand for high-immunogenicity vaccines is expected to rise continuously due to global aging and the increasing number of immunocompromised individuals and those with chronic illnesses. SKYCellflu, SK bioscience's existing cell-based influenza vaccine, has already been recognized for its innovation. It became the world's first cell-based flu vaccine to receive prequalification (PQ) from the WHO and is currently approved in 11 countries, with supply through international procurement programs by United Nations Children's Fund (UNICEF) and Pan American Health Organization (PAHO). Jaeyong Ahn, CEO of SK bioscience, said, "We believe the combination of our proven SKYCellflu platform and our experience in adjuvanted vaccine development positions us well for success. We aim to establish a differentiated presence in the high-immunogenicity vaccine market while building a flexible platform for future infectious disease preparedness."

GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam

Korea Herald

time17-07-2025

  • Korea Herald

GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam

YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy—pursuing both global procurement channels and direct market entry initiatives. To obtain approval in Vietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primarily to children, quality certification holds particular importance in the varicella segment. GC Biopharma plans to establish stable annual revenue in Vietnam by leveraging its local affiliate to engage directly in sales activities, in consideration of the country's private market-oriented vaccine distribution system. From 2018 to 2021, Vietnam's private vaccine market recorded a compound annual growth rate (CAGR) of 32%, reaching approximately USD 300 million in 2021. Varicella vaccines accounted for nearly 10% of the private market [1], with demand for private vaccinations continuing to grow steadily. "This marketing authorization represents more than a product export—it is the result of a localization strategy and a significant step toward expansion in Southeast Asia," said Jae Woo Lee, Head of Development Department at GC Biopharma. "We will continue to strengthen our position as a trusted vaccine brand by delivering clinical and quality standards that meet global expectations." BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. The vaccine is characterized by high viral titer and manufacturing yield. Notably, BARYCELA is the world's first varicella vaccine produced without antibiotics, utilizing a fully aseptic manufacturing process. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo ® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Sohee Kim Yelin Jun

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store